TELO Telo Genomics Corporation

Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that the Company has presented the results of its Hodgkin’s lymphoma (HL) clinical study at ASH 2020.

The large multicenter study included participants from 3 national and international centers. An abstract summarizing the data was presented at ASH 2020. Although the abstract was included in the proceedings of ASH 2020, the detailed results are embargoed until the manuscript comprising the full study results is published.

The study builds on previous proof of concept published reports using TeloView®, suggesting a clinical utility for the TeloView® technology as a prognostic tool for the management of classic Hodgkin’s lymphoma patients from point of diagnosis.   

The American Society of Hematology is a professional organization representing healthcare professionals involved in the management of blood disorders including blood cancers. The ASH annual meeting is considered the top clinical international meeting focused on blood cancers and lymphoid malignancies. ASH annual meeting attracts more than 30,000 attendees every year, predominantly clinicians from all over the world.

Hodgkin’s lymphoma (HL) is a malignancy that affects both genders of all age groups. Approximately 75-80% of newly diagnosed HL patients respond favorably to the traditional first line treatment (ABVD), while 20-25% will show resistance to this approach. To date there is no prognostic tool in the clinic that can identify HL patients who will or will not respond to the traditional first line treatment.

The Company also wishes to congratulate Dr. Hans Knecht, MD, Professor of Medicine and Chief, Division of Haematology at McGill University and Jewish General Hospital, Montreal, Canada, for being honoured and awarded recently the 2020 prize for “Cutting Edge Hematology” at the 57th Jewish General Hospital’s Annual Andre Aisenstadt Clinical Day. The prize is shared with Dr. S. Caplan, his predecessor in these functions. Dr. Knecht is a long-term collaborator with Telo Genomics and Dr. Mai, Director and Chair of the Clinical and Scientific Advisory Board (CSAB) of TELO. Dr. Knecht is also a member of TELO’s CSAB.

“We are excited to present the results of the HL clinical study at ASH 2020,” said Sherif Louis, TELO’s CEO. “The HL study is a powerful indicator about TeloView®’s utility in the management of blood cancers in general, and particularly TELO’s lead indication multiple myeloma.”

About Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information please visit www.telodx.com.

For further information, please contact:

Hugh Rogers, Director416-673-8487info@telodx.comMaRS Centre, South Tower, 101 College Street, Suite 200, Toronto, ON, M5G 1L7www.telodx.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “intends”, “will”, or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloViewTM platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.